81. 先天性副腎皮質酵素欠損症 Congenital adrenal hyperplasia Clinical trials / Disease details

臨床試験数 : 87 / 薬物数 : 87 - (DrugBank : 23) / 標的遺伝子数 : 12 - 標的パスウェイ数 : 68

diseases per page:

Showing 1 to 10 of 87 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03548246 (ClinicalTrials.gov)	January 2023	24/4/2015	Androgen Reduction in Congenital Adrenal Hyperplasia	A Phase 1-2 Multi-Center Study to Assess the Efficacy and Safety of Abiraterone Acetate as Adjunctiv ...	Congenital Adrenal Hyperplasia	Drug: Abiraterone acetate;Drug: Placebo;Drug: Hydrocortisone;Drug: Fludrocortisone	University of Texas Southwestern Medical Center	National Institutes of Health Clinical Center (CC);University of Michigan;Children's Hospital Los An ...	Withdrawn	2 Years	9 Years	All	0	Phase 2	United States
2	NCT05669950 (ClinicalTrials.gov)	December 19, 2022	20/12/2022	Study of Lu AG13909 in Participants With Congenital Adrenal Hyperplasia	A Multi-site, Open-label, Sequential-group, Multiple-ascending-dose Study to Investigate the Safety, ...	Congenital Adrenal Hyperplasia	Drug: Lu AG13909	H. Lundbeck A/S	NULL	Recruiting	18 Years	55 Years	All	12	Phase 1	United Kingdom
3	NCT05299554 (ClinicalTrials.gov)	April 1, 2022	5/1/2022	Long-term Safety Study of Chronocort in the Treatment of Participants With Congenital Adrenal Hyperp ...	A Phase 3 Open-Label Extension Study to Evaluate the Long-term Safety and Tolerability of Chronocort ...	Congenital Adrenal Hyperplasia	Drug: Chronocort	Diurnal Limited	NULL	Enrolling by invitation	16 Years	N/A	All	181	Phase 3	United States;France
4	EUCTR2019-004764-22-IT (EUCTR)	12/01/2022	07/10/2021	This is a randomized, double-blinded, Placebo controlled trial with a 3-part treatment period that w ...	A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safe ...	Classic Congenital Adrenal Hyperplasia MedDRA version: 20.0;Level: LLT;Classification code 10010323; ...	Product Name: Tildacerfont Product Code: [SPR001] INN or Proposed INN: TILDACERFONT Trade Name: HYDROCO ...	Spruce Biosciences Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	72	Phase 2	United States;Canada;Poland;Spain;Denmark;Australia;Netherlands;Germany;United Kingdom;Italy;Sweden
5	JPRN-jRCT2031210491	04/01/2022	17/12/2021	Double-blind comparison of Chronocort versus standard hydrocortisonereplacement therapy in participa ...	A randomized, Double-Blind, Active-Controlled, Phase 3 Study ofChronocort Compared with Immediate-Re ...	Congenital adrenal hyperplasia (CAH)	Participants randomized to Chronocort will receive 10 mg Chronocort in the morning on waking (typica ...	Fujii Katsuya	NULL	Recruiting	>= 16age old	Not applicable	Both	15	Phase 2	US;France;Turkey;Japan
6	EUCTR2020-004381-19-DE (EUCTR)	16/12/2021	09/04/2021	Study to Evaluate the Safety and Efficacy of Crinecerfont in Pediatric Patients With Classic Congeni ...	A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecer ...	Classic Congenital Adrenal Hyperplasia(CAH) MedDRA version: 20.0;Level: LLT;Classification code 1001 ...	Product Name: Crinecerfont Product Code: NBI-74788 INN or Proposed INN: Crinecerfont Product Name: Crin ...	Neurocrine Biosciences, Inc.	NULL	Not Recruiting			Female: yes Male: yes	81	Phase 3	France;United States;Greece;Canada;Spain;Poland;Belgium;Germany;United Kingdom;Italy;Sweden
7	NCT05063994 (ClinicalTrials.gov)	December 13, 2021	28/5/2021	Comparison of Chronocort Versus Standard Hydrocortisone Replacement Therapy in Participants Aged 16 ...	A Randomized, Double-Blind, Active-Controlled, Phase 3 Study of Chronocort Compared With Immediate-R ...	Congenital Adrenal Hyperplasia	Drug: Chronocort;Drug: Cortef	Diurnal Limited	NULL	Recruiting	16 Years	N/A	All	150	Phase 3	United States;France;Japan
8	NCT05128942 (ClinicalTrials.gov)	December 10, 2021	27/10/2021	A Phase 2 Study to Evaluate the Safety, Efficacy and PK of Tildacerfont in Children With CAH	A Phase 2 Study to Evaluate the Safety, Efficacy and Pharmacokinetics of SPR001 (Tildacerfont) in Ch ...	Congenital Adrenal Hyperplasia;21-OHD	Drug: Tildacerfont	Spruce Biosciences	NULL	Recruiting	2 Years	17 Years	All	20	Phase 2	United States
9	EUCTR2020-004381-19-IT (EUCTR)	13/10/2021	30/08/2021	Study to Evaluate the Safety and Efficacy of Crinecerfont in Pediatric Patients With Classic Congeni ...	A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecer ...	Congenital adrenal hyperplasia(CAH) is a group of rare inherited endocrine disorders characterized b ...	Product Name: Crinecerfont Product Code: [NBI-74788] Other descriptive name: Crinecerfont is a novel no ...	Neurocrine Biosciences, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	81	Phase 3	France;United States;Greece;Canada;Spain;Poland;Belgium;Germany;Italy;Sweden
10	EUCTR2020-004381-19-ES (EUCTR)	13/08/2021	13/08/2021	Study to Evaluate the Safety and Efficacy of Crinecerfont in Pediatric Patients With Classic Congeni ...	A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecer ...	Classic Congenital Adrenal Hyperplasia(CAH) MedDRA version: 20.0;Level: LLT;Classification code 1001 ...	Product Name: Crinecerfont Product Code: NBI-74788 INN or Proposed INN: Crinecerfont Product Name: Crin ...	Neurocrine Biosciences, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	81	Phase 3	France;United States;Greece;Canada;Poland;Belgium;Spain;Germany;Italy;Sweden

First Previous1 2 3 4 5…9Next Last